Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.

Separately, company executives said they expect an immaterial impact to the company from proposed U.S ... the Rahway, New Jersey, company. For the recently completed fourth quarter, Merck booked ...

Merck & Co. (MRK) on Tuesday reported fourth-quarter net income of $3.74 billion. On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.48. Earnings, adjusted for one ...

Keytruda, also known as pembrolizumab, accounts for the bulk of the Rahway, New Jersey-based pharmaceutical giant's revenue. However, with its U.S. patent exclusivity ending in 2028, Merck (NYSE ...

Rahway, New Jersey-based Merck & Co., Inc. (MRK ... MRK’s underperformance is apparent compared to the iShares U.S. Pharmaceuticals ETF (IHE). The exchange-traded fund has gained about ...

RAHWAY – There's a special new landmark to check out on the NJ Transit train ride south into ... train stations on the right side near the Merck facility, pays tribute to Nikola Tesla, Carl ...